沙培林联合顺铂胸腔内注入治疗恶性胸腔积液疗效观察

Efficacy of picibznii and cisplatine influxed into thoracic cavity for treating malignant pleural effusion

目的探讨胸腔注入顺铂（DDP）联合沙培林治疗恶性胸腔积液的疗效。方法病理诊断恶性胸腔积液80例，经胸腔插管引流术排尽胸液后，按随机化原则分为两组，治疗组42例，对照组38例。治疗组在胸腔内注入沙培林＋DDP，对照组胸腔注入顺铂。观察疗效、毒副反应，生活质量及生存率。结果治疗组总有效率88％，病变进展率4．7％，较对照组（37％、28％）差异有统计学意义（P〈0．05）。Kamofshky的平分〉70分，治疗组较对照组有显著提高（P〈0．05）。治疗组0．5、1、1．5、2年的生存率为95％、66％、52％、9％，分别高于对照组76％、37％、16％、3％，其中0．5、1．5年后生存率差异有统计学意义（P〈0．05）。结论应用沙培林和顺铂治疗恶性胸腔积液安全有效，副作用低，是治疗恶性胸腔积液的理想药物。

Objective To evaluate the efficacy of picibznil and cisplatine influxed into thoracic cavity for treating malignant pleural effusion. Methods After malignant pleural effusion was abstracted completely out, 80 patients with maligant pleural effusion were divided into two groups at random： study group （group Ⅰ ）and control groud （group Ⅱ ）, group I were influxed picibznil and cisplatine into pleural cavity ; group Ⅱ were only influxed cisplatine. We observed these patients＇ curative efficacy, side reaction, quality of life and surviral rate. Results In group Ⅰ, the tolal effective rate was 88% ;group Ⅱ was 37%. There was obviously difference between group Ⅰ and group Ⅱ （ P 〈 0.05 ）. The karnofsky score of group Ⅰ was higher than group Ⅱ. In group Ⅰ , patients＇ survival rate was longer and group Ⅱ in 0.5year, 1 year, 1.5 year, 2 year. Conclusion Picibznil combined with cisplatine is used to treat malignant pleual effusion. This method is safe and effective. These drugs are ideal drugs about treating malignant plenral effusion.